Why Is TELIX PHARMACEUTICAL ADR (TLX) Stock Down Today?

Telix Pharmaceuticals shares fell 10.13% to $10.03, marking a sharp decline despite the company reporting third-quarter revenue growth of 19% to $245 million. The primary driver of the sell-off appears to be a reassessment of the stock's valuation following the release of its financial update, which reaffirmed its full-year 2026 revenue and other income view above $1 billion.

What Happened

Telix Pharmaceuticals reported third-quarter 2026 group revenue of $245 million, up from $206 million in the same period last year. Precision medicine revenue increased 30% year over year to $201 million, driven by demand for Gozellix and Illuccix. The company reaffirmed its outlook for full-year 2026 revenue and other income to exceed $1 billion, tracking toward the upper end of its $950 million to $970 million guidance. Additionally, Telix revised its research and development spend guidance to between $240 million and $260 million. Wedbush reiterated its Outperform rating on the stock, maintaining a $22 price target. The company also announced a collaboration with Ekalia, an IBA-Framatome joint venture, to secure priority access to Astatine-211 for its TLX102-Tx glioblastoma pipeline.

What The Data Shows

The stock printed four fresh 52-week lows on October 21, 2026, despite trading within its 52-week range of $6.28 to $13.11. Fundamentals show a market capitalization of $3.7 billion with a price-to-earnings ratio of 117.0. Trailing twelve-month revenue growth stands at 33.5%, while the net margin is 3.8%. The stock has a beta of 0.56. Over the last eight sessions, the stock moved down 10.9% from $11.29 to $10.06. Recent insider activity includes a buy by Group CFO Darren Charlton on September 7, 2026, with one buy totaling $20,000 in the last 90 days and no sells.

What To Watch

Investors will monitor how the market digests the updated R&D outlook and the reaffirmed revenue targets. The stock's recent trend of printing new lows suggests continued volatility as traders adjust to the valuation metrics.